PCSK9 Inhibitors in Combination With Advanced Treatment Strategies for the Treatment of Advanced Colorectal Cancer With pMMR/MSS - Trial NCT06391905
Access comprehensive clinical trial information for NCT06391905 through Pure Global AI's free database. This Phase 2 trial is sponsored by Guangdong Provincial People's Hospital and is currently Not yet recruiting. The study focuses on Colorectal Cancer. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
PCSK9 inhibitor in combination with standard advanced first-line regimen group
Interventional
drug
Sponsor & Location
Guangdong Provincial People's Hospital
Timeline & Enrollment
Phase 2
May 06, 2024
May 06, 2028
Primary Outcome
Objective response rateObjective response rate (ORR)
Summary
The purpose of this study is to preliminarily observe the efficacy and safety of PCSK9
 inhibitors in combination with standard advanced first-line regimens in the treatment of
 advanced colorectal cancer with pMMR/MSS.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06391905
Non-Device Trial